

Racial Disparities in Clinical Outcomes of Veterans Affairs Residential PTSD Treatment Between Black and White Veterans

Georgina M. Gross, Ph.D., Noelle Smith, Ph.D., Ryan Holliday, Ph.D., David C. Rozek, Ph.D., Rani Hoff, Ph.D., Ilan Harpaz-Rotem, Ph.D.

Objective: Racial disparities across various domains of health care are a long-standing public health issue that affect a variety of clinical services and health outcomes. Mental health research has shown that prevalence rates of posttraumatic stress disorder (PTSD) are high for Black veterans compared with White veterans, and some studies suggest poorer clinical outcomes for Black veterans with PTSD. The aim of this study was to examine the impact of racial disparities longitudinally in the U.S. Department of Veterans Affairs (VA) residential rehabilitation treatment programs (RRTPs).

Methods: Participants included 2,870 veterans treated nationally in VA PTSD RRTPs in fiscal year 2017. Veterans provided demographic data upon admission to the program. Symptoms of PTSD and depression were collected at admission, discharge, and 4-month follow-up. Hierarchical

linear modeling was used to examine symptom change throughout and after treatment.

Results: Black veterans experienced attenuated PTSD symptom reduction during treatment as well as greater depression symptom recurrence 4 months after discharge, relative to White veterans.

Conclusions: This study adds to the body of literature that has documented poorer treatment outcomes for Black compared with White veterans with PTSD. Although both Black and White veterans had an overall reduction in symptoms, future research should focus on understanding the causes, mechanisms, and potential solutions to reduce racial disparities in mental health treatment.

Psychiatric Services 2022; 73:126–132; doi: 10.1176/appi.ps.202000783

Posttraumatic stress disorder (PTSD) is a pressing mental health concern among U.S. veterans, with prevalence estimates around 23% for veterans of Operation Enduring Freedom and Operation Iraqi Freedom (OEF/OIF) (1). The U.S. Department of Veterans Affairs (VA) health care system provides a variety of treatment services for veterans with PTSD, including residential rehabilitation treatment programs (RRTPs) and has made optimizing care for individuals with PTSD a high priority (2). The purpose of this study was to examine racial disparities in clinical outcomes of VA PTSD RRTPs.

Racial disparities in disease burden and differences in the quantity and quality of health care between Black and White Americans are significant long-standing public health concerns (3). Racism, discrimination, limited economic resources, segregation, restricted housing opportunities, chronic stress, and many other variables contribute to poorer mental and general medical health and restricted health care for Black Americans (4). Furthermore, widespread unequal treatment of Black patients by non-Black health care providers has

been well documented (5). The VA is a unique health care system in that financial barriers to accessing private-sector health care (e.g., insurance coverage, income), which disproportionately affect Black Americans, are not directly present (3, 6). Nonetheless, racial disparities in clinical outcomes and receipt of health care across a range of VA clinical services

HIGHLIGHTS

- This study examined racial disparities in mental health treatment for veterans with posttraumatic stress disorder (PTSD) participating in the U.S. Department of Veterans Affairs residential rehabilitation treatment programs (RRTPs).
- Results indicate that RRTPs reduce symptoms of PTSD and depression among veterans.
- Black veterans, compared with White veterans, experienced attenuated symptom reduction and increased symptom recurrence after discharge.

(e.g., heart and vascular disease, preventive and ambulatory care, mental health, and substance use) have been identified (6). Current examinations of disparities in mental health treatment for veterans are needed to inform optimal care for individuals with PTSD.

The research literature has indicated higher prevalence and severity of PTSD among Black relative to White veterans. Black veterans who recently ended active duty military service (within the past 90 days) were more likely to screen positive for PTSD (36.3%) than were any other racial-ethnic group, including White veterans (22.5%) (7). Compared with White counterparts, Black veterans were also more likely to screen positive for PTSD in a population-based cohort of OEF/OIF veterans (8). Black active duty service members reported more severe PTSD symptoms (9), and Black Vietnam War veterans have shown elevated rates and severity of PTSD compared with White veterans (10, 11). However, one study of OEF/OIF veterans and veterans of Operation New Dawn (OND) found higher rates of PTSD for Black men but not for Black women (12), and, in a sample of veterans from service eras before OEF/OIF/OND, no differences in PTSD by race were reported (13).

Studies have also reported racial disparities in access to and receipt of mental health treatment for veterans with PTSD, although results have been mixed. Black veterans with PTSD were less likely to receive a minimally adequate dose of pharmacotherapy (i.e., 120 days of antidepressants) and any treatment in the 6 months after diagnosis. This disparity remained when accounting for personal beliefs about mental health treatment (14). Other studies have corroborated that Black veterans with PTSD are less likely to receive any therapy (15), individual therapy (16), or a minimally adequate dose of treatment (at least nine mental health outpatient visits within a 15-week period or at least 12 consecutive weeks of medication use) within the first year of initiating treatment (17) or a medication trial (18); less likely to complete PTSD treatment (19); and experience longer wait times before their first appointment (20). Alternatively, some studies have indicated that Black (compared with White) veterans with PTSD are more likely to receive counseling (18) and a greater number of psychotherapy appointments (21) and that Black men were more likely than White men to use outpatient mental health care (22).

Similarly, research remains mixed in terms of clinical outcomes of PTSD treatment among Black veterans. Lester and colleagues (19) noted that Black veterans had PTSD treatment response similar to that of White veterans. This finding was similarly upheld within a sample of Black and White veterans receiving treatment for military sexual assault-related PTSD (23). However, these prior evaluations were within the context of clinical trials, most of which have not reported outcomes by racial groups and differ contextually from routine clinical practice.

When the role of race on treatment outcomes was analyzed within real-world samples, differing results were reported. In a national study of clinical outcomes 6 months

after receiving a PTSD diagnosis, Black veterans were less likely than White veterans to show significant improvement in PTSD symptoms (24). This was true among both treatment initiators and noninitiators, indicating that differences in treatment initiation were not driving this disparity. These findings are consistent with other national studies showing poorer clinical outcomes for Black veterans with PTSD in VA outpatient mental health treatment (25, 26). Studies have also reported that non-White race is associated with poorer response to cognitive processing therapy for PTSD (27). However, one study reported that Black veterans showed greater improvement from prolonged exposure therapy than other races (28). Overall, more work is needed to elucidate and address potential racial disparities in clinical outcomes.

The VA PTSD residential treatment setting has not been adequately examined for racial disparities in clinical outcomes. One study of veterans in VA PTSD RRTPs from 2012 to 2013 reported that, compared with White veterans, Black veterans had 30% lower odds of clinically significant improvement (29). Otherwise, information on race in the VA PTSD RRTP setting has largely been limited to the inclusion of race as a covariate (30). Given that veterans treated in VA PTSD RRTPs often have more severe treatment needs and a different treatment setting (31), further examination is needed.

The goal of the current study was to characterize whether Black veterans admitted to VA PTSD RRTPs differed from White veterans in initial PTSD and depressive symptom severity and program completion. We also sought to examine the role of race on PTSD and depressive symptom change over the course of and after treatment by using a hierarchical linear modeling (HLM) approach. We hypothesized that Black and White veterans would experience reductions in PTSD and depressive symptoms; however, given prior research, we hypothesized that symptom reduction would be less for Black veterans.

METHODS

Participants and Procedure

Participants included veterans who initiated VA PTSD residential treatment during fiscal year 2017 (i.e., October 1, 2016, through September 30, 2017). As part of the Northeast Program Evaluation Center's (NEPEC) program evaluation of VA PTSD treatment, veterans completed self-report measures at admission and discharge. Approximately 4 months after discharge, all veterans received voluntary self-report measures via mail. The current study included data from 44 RRTPs. Average length of stay was 51 days (range 3–322 days). NEPEC does not collect data for veterans with admissions lasting less than 3 days. VA PTSD RRTPs vary in length and programming. General admission criteria included not currently meeting criteria for an acute psychiatric or medical admission, previous participation in a less restrictive treatment alternative (if available), needing an intensive level of care, not being at significant acute risk of harm to self or

others, and being capable of basic self-care. Veterans who completed an intake form at admission and who self-identified their race as White or Black (N=2,870) were included in the present analyses. This study was approved by the VA Connecticut Healthcare System Institutional Review Board.

Measures

Veterans provided race and other demographic information on the admission form, including age, sex, ethnicity (Hispanic vs. not), and years of education. The race variable options were not mutually exclusive. All veterans who identified as Black (including multiracial) were included in the Black category, whereas the White category did not include multiracial identities. Other race categories (American Indian/Alaskan, Asian, Pacific Islander, "other," and "prefer not to answer") were excluded from the analyses because of small sample sizes precluding modeling (N=282, 6%, with even smaller cell sizes in each category).

Veterans indicated whether they had experienced military sexual trauma (MST) by answering the question, "Which type of traumatic incident (include both military and nonmilitary) have you suffered within your lifetime? (Check all that apply.)" Combat experience was assessed with the question, "Did you ever receive friendly or hostile incoming fire from small arms, artillery, rockets, mortars, or bombs?" This approach has been used in prior evaluations (32).

PTSD symptoms at admission, discharge, and follow-up were assessed by using the PTSD Checklist for DSM-5 (PCL-5) (33). The PCL-5 contains 20 items corresponding with the *DSM-5* diagnostic criteria for PTSD. Possible scores range from 0 to 80, with higher scores indicating more severe PTSD symptoms. The PCL-5 has established psychometric properties (34) and is widely used to monitor PTSD symptoms in response to treatment (35).

Depressive symptoms at admission, discharge, and follow-up were assessed by using the Patient Health Questionnaire-9 (PHQ-9) (36), which contains nine items corresponding with *DSM-IV-TR* (37) diagnostic criteria for major depressive disorder. Possible scores range from 0 to 27, with higher scores indicating more severe depressive symptoms. The PHQ-9 has sound psychometric properties and is widely used as a brief diagnostic and severity measure (38).

Finally, veteran records were matched to the electronic medical record to obtain length of stay and the Veterans Integrated Service Network (VISN) (or geographic region in the United States based on Veterans Health Administration designation) where the PTSD RRTP took place.

Analytic Plan

Bivariate analyses (i.e., Pearson's chi-square for categorical variables and t tests for continuous variables) were conducted to determine significant differences in demographic variables (i.e., age, sex, ethnicity, education), experience of military-related trauma (i.e., MST, combat), rates of program completion, VISN of the PTSD RRTP, and length of RRTP stay.

Factors determined to be significantly different by race were included in models as covariates.

HLM was then conducted by using SPSS, version 26.0. This approach was chosen on the basis of its ability to handle missing longitudinal data and to more accurately model variance than a repeated-measures analysis of variance (39, 40). In the two models (i.e., one for PTSD symptoms and the other for depressive symptoms), lower-level, or level-1, data comprised repeated symptom measure (PCL-5 and PHQ-9, respectively) scores collected at admission, discharge, and follow-up. Each model was implemented at discharge to identify posttreatment symptom differences by race. On the basis of visual analysis of the growth curve a segmented growth was identified with linear change from admission to discharge and discharge to 4-month follow-up modeled (41).

Level-1 data were then nested within upper-level, or level-2 fixed-effect, units (i.e., White, 0; Black, 1). Because of large sample size, a maximum likelihood approach was used, with a conservative threshold for statistical significance ($\alpha=0.001$). Model fit was assessed by using deviance and a chi-square difference test between models. An autoregressive structure was used (41, 42).

RESULTS

Demographic variables, military trauma, program completion, and PCL-5 and PHQ-9 scores at admission can be found in Table 1. Overall, age, ethnicity, education, exposure to combat, exposure to MST, and VISN of PTSD RRTP were all found to significantly differ between White and Black veterans ($p<0.001$). As such, these variables were included in the PCL-5 and PHQ-9 models as level-1 fixed effects. Additionally, length of stay differed between groups at a standard level of significance ($p<0.05$). On the basis of statistical consultation and inclusion in prior studies examining PTSD RRTP effectiveness (29), we included length of stay as a level-1 fixed effect as well as a level-2 fixed effect nested into repeated symptom measurement.

Across models, PCL-5 scores were available for 1,848 veterans at discharge and 1,071 at follow-up. PHQ-9 scores were available for 1,699 veterans at discharge and 1,068 at follow-up. Missing data did not differ statistically significantly on the basis of race. Figure 1 presents change in PTSD and depressive symptoms across the three timepoints.

PTSD Symptoms Model

Results indicated a significant decrease in PTSD symptoms over the course of treatment ($\beta=-14.26$, $t=-30.14$, $df=2,994$, $p<0.001$), followed by a significant recurrence of PTSD symptoms over follow-up ($\beta=5.90$, $t=9.40$, $df=2,494$, $p<0.001$). When race was added as a level-2 fixed-effect variable, a significant association was found during treatment such that Black veterans experienced an attenuated response over the course of the PTSD RRTP ($\beta=3.31$, $t=3.93$, $df=2,765$, $p<0.001$). Moreover, the main effect of race at intercept was also significant ($\beta=5.24$, $t=6.40$, $df=4,516$, $p<0.001$),

indicating that Black veterans had significantly greater PCL-5 scores at discharge. A main effect of race during follow-up was not detected, suggesting similar slopes of PTSD symptom recurrence among Black and White veterans. Table 2 provides the complete model.

Depressive Symptoms Model

Similarly, depressive symptoms decreased over the course of treatment ($\beta=-4.57$, $t=-32.85$, $df=3,038$, $p<0.001$), and veterans experienced a significant recurrence from discharge to 4-month follow-up ($\beta=2.71$, $t=14.91$, $df=3,528$, $p<0.001$). Differing from the PCL-5 model, when race was included as a level-2 fixed effect, in this model race only trended toward significance, on the basis of the conservative threshold, as it related to change from admission to discharge. However, a main effect for race was determined during follow-up such that Black veterans experienced significantly more recurrence in depression symptoms relative to White veterans ($\beta=1.70$, $t=3.99$, $df=3,034$, $p<0.001$). Additionally, the main effect of race at intercept trended toward significance. Table 3 shows the complete model.

DISCUSSION

Building upon prior examinations (29), this is the first study to examine differences between Black and White veterans on longitudinal residential outcomes of PTSD and depressive symptoms during and after a VA PTSD RRTP. In general, Black and White veterans experienced significant symptom reduction during RRTP participation. However, consistent with our hypotheses, Black veterans experienced attenuated PTSD symptom reduction during treatment as well as greater depressive symptom recurrence from discharge to 4-month follow-up. These results are consistent with prior studies demonstrating poorer clinical outcomes associated with both outpatient (24–26) and residential (29) treatment for Black, relative to White, veterans with PTSD. Consistent with prior literature, we also found that Black veterans reported greater PTSD symptoms at admission (9–11).

Our study did not allow for determination of the causes of these disparities; however, recent literature highlights the need to improve mental health care for Black veterans with PTSD. Spont et al. (24) reported poorer clinical outcomes for Black veterans regardless of whether they initiated treatment, and furthermore, that racial disparities in PTSD outcomes were greater among treatment initiators, indicating that treatment selectively improved outcomes for White veterans. Similarly, the current study showed disparities in symptom outcomes, but no significant differences in rates of program completion for Black veterans compared with


TABLE 1. Demographic characteristics of veterans (N=2,870), by race^a

Characteristic	White (N=2,036)		Black (N=834)		Test statistic	df	p
	N	%	N	%			
Female	217	11.2	108	13.4	$\chi^2=2.55$	1	ns
Hispanic	264	13.0	55	6.6	$\chi^2=24.31$	1	<.001
Military sexual trauma	357	17.5	255	30.6	$\chi^2=59.98$	1	<.001
Combat	1,579	80.1	510	64.6	$\chi^2=73.66$	1	<.001
Completed program	1,450	72.1	604	72.4	$\chi^2=.42$	1	ns
Age (M±SD years)	42.75±12.16		51.26±11.96		$t=-17.11$	2,865	<.001
Education (M±SD years)	13.50±2.23		13.16±2.09		$t=3.79$	1,586	<.001
PCL-5 at admission (M±SD)	58.43±12.28		59.54±12.55		$t=-2.18$	2,868	<.05
PHQ-9 at admission (M±SD)	17.88±5.38		17.45±5.52		$t=1.80$	2,609	ns
Length of stay (M±SD)	50.28±23.53		52.43±21.46		$t=-2.26$	2,853	<.05

^a Scores on the PTSD Checklist for DSM-5 (PCL-5) range from 0 to 80, with higher scores indicating more severe PTSD symptoms. Scores on the Patient Health Questionnaire-9 (PHQ-9) range from 0 to 27, with higher scores indicating more severe depressive symptoms. ns, nonsignificant.

White veterans. Thus, components of treatment that may be contributing to racial disparities in outcomes should be examined.

FIGURE 1. Change in PCL-5 and PHQ-9 scores during VA RRTP participation and follow-up, by race^a



^a A: possible scores on the PTSD Checklist for DSM-5 (PCL-5) range from 0 to 80, with higher scores indicating more severe PTSD symptoms. B: Possible scores on the Patient Health Questionnaire-9 (PHQ-9) range from 0 to 27, with higher scores indicating more severe depressive symptoms. RRTP, residential rehabilitation treatment program; VA, U.S. Department of Veterans Affairs.

TABLE 2. Longitudinal model of PTSD symptom change from VA RRTP admission to 4-month follow-up^a

Variable	β	SE	t	df	95% CI	p
Intercept	48.34	2.27	21.30	3,066	43.89, 52.79	<.001
Change from admission to discharge	-11.34	1.14	-9.97	2,983	-13.58, -9.11	<.001
Change from discharge to 4-month follow-up	5.63	1.44	3.90	3,324	2.78, 8.46	<.001
Age	-.11	.02	-4.92	2,405	-.15, -.06	<.001
Combat trauma	1.75	.69	2.52	2,429	.39, 3.11	ns
Military sexual trauma	1.49	.73	2.06	2,410	.07, 2.91	ns
Education	-.03	.12	-.27	2,375	-.26, .20	ns
VISN	.05	.04	1.19	2,464	-.03, .12	ns
LOS	-.03	.02	-1.81	4,771	-.07, <.01	ns
LOS × change from admission to discharge	-.07	.02	-3.42	2,977	-.11, -.03	ns
LOS × change from discharge to 4-month follow-up	-.01	.26	-.39	3,336	-.06, .04	ns
Race	5.24	.82	6.40	4,516	3.63, 6.85	<.001
Race × change from admission to discharge	3.31	.84	3.93	2,765	1.66, 4.96	<.001
Race × change from discharge to 4-month follow-up	1.09	1.10	.99	3,297	-1.07, 3.25	ns

^a LOS, length of stay; ns, nonsignificant; RRTP, residential rehabilitation treatment program; VA, U.S. Department of Veterans Affairs; VISN, Veterans Integrated Service Network.

One such component is the working alliance between veteran and provider, which has been documented as being less strong between Black veterans and their providers (43). This disparity has been attributed to lack of provider cultural competence and empathy and veteran experiences of racial bias. Spont et al. (16) reported that for treatment retention for Black veterans with PTSD, patient-rated satisfaction with

that some Black veterans may hesitate to engage in care. Some studies have reported that, compared with White veterans, Black veterans are more likely to delay initiation of PTSD treatment (48), have less confidence in managing their mental health care (43), are less willing to speak to psychiatrists or psychologists about mental health (49), and may be more likely to discontinue treatment prematurely (50). It should

TABLE 3. Longitudinal model of depressive symptom change from VA RRTP admission to 4-month follow-up^a

Variable	β	SE	t	df	95% CI	p
Intercept	14.23	.91	15.60	2,849	12.44, 16.03	<.001
Change from admission to discharge	-4.18	.44	-9.46	2,700	-5.04, -3.31	<.001
Change from discharge to 4-month follow-up	3.03	.55	5.48	3,015	1.95, 4.11	<.001
Age	-.04	.01	-4.80	2,267	-.06, -.02	ns
Combat trauma	.44	.28	1.54	2,287	-.12, .99	ns
Military sexual trauma	.44	.30	1.50	2,262	-.14, 1.03	ns
Education	.03	.05	.58	2,219	-.06, .12	ns
VISN	.02	.02	1.58	2,301	-.01, .06	ns
LOS	-.01	.01	-1.03	4,487	-.02, .01	ns
LOS × change from admission to discharge	-.01	.01	-1.35	2,720	-.03, <.01	ns
LOS × change from discharge to 4-month follow-up	-.02	.01	-1.69	3,024	-.04, <.01	ns
Race	.68	.33	2.05	4,262	.03, 1.33	ns
Race × change from admission to discharge	.68	.34	2.02	2,542	.02, 1.33	ns
Race × change from discharge to 4-month follow-up	1.70	.43	3.99	3,034	.87, 2.54	ns

^a LOS, length of stay; ns, nonsignificant; RRTP, residential rehabilitation treatment program; VA, U.S. Department of Veterans Affairs; VISN, Veterans Integrated Service Network.

providers was more important than beliefs about treatment. Black veterans in VA mental health care have reported experiences of being judged, feared, and/or stereotyped in clinical encounters (44, 45). Black veterans voiced preference for Black therapists and cited past experiences of cultural insensitivity and racial bias from White therapists (46).

In addition, Black veterans in VA mental health care reported a lack of minority representation, including in the characteristics of the physical space and lack of staff diversity, in particular in positions of power (44). Minority identities, including Black identities, continue to be dramatically underrepresented among psychologists (47). Given this context, it is not surprising

that many participants in the above studies reported positive experiences with VA mental health treatment. However, given these disparities in clinical outcomes and experiences of PTSD treatment, a continued focus on providing care that is welcoming, effective, and satisfactory to Black veterans is warranted. Furthermore, as noted above, financial factors, such as insurance coverage and affordability of treatment that disproportionately affect Black Americans are not a direct factor in the VA, yet evidence for mental health disparities persists. Therefore, the VA presents a unique opportunity to both understand and address other barriers to equitable mental health care for Black veterans.

Finally, poorer clinical outcomes for Black veterans with

PTSD in our study and the literature more broadly may be due to elevated levels of stress. Members of nondominant racial groups are exposed to a greater number of stressors (including race-based discrimination) throughout life, which are directly linked to health disparities, including PTSD (4, 51). Black veterans have reported greater perceived threat and family stressors during deployment (52), higher rates of MST (as found in the current study) (53), higher postdeployment life stress (veterans who recently ended active duty military service) (7), race-based discrimination (45), and lower education levels and income (54). Thus, PTSD treatment for Black veterans may be enhanced by assessing for and directly addressing race-based stress when relevant. Such an approach is consistent with an intersectionality model, which considers how factors such as discrimination and privilege contribute to mental health (55).

These results should be interpreted in the context of several limitations. Although we controlled for ethnicity in analyses, we did not have adequate sample sizes to include racial-ethnic categories outside of Black and White. (Note that members of other categories were included in our analyses if they also identified as Black.) In addition, although HLM is more equipped to handle missing data than other analytic approaches (39, 40), missing data may limit generalizability of findings to all veterans who participate in PTSD RRTPs.

Additionally, we were unable to examine characteristics of individual RRTP sites, such as the percentage of Black veterans enrolled and the percentage of Black therapists and staff members. We also did not have access to information regarding specific treatments obtained by veterans while in a PTSD RRTP (e.g., cognitive processing therapy, prolonged exposure therapy) or mental health treatment engagement between discharge and follow-up. Therefore, additional research examining the role of program-based differences and how they may affect therapeutic response related to race remains an important future direction.

CONCLUSIONS

Our results indicated that among a national sample of veterans who completed a VA PTSD RRTP in fiscal year 2017, veterans generally benefited from treatment. Nonetheless, Black veterans experienced decreased therapeutic response during and after treatment relative to White veterans. Future research should further examine mechanisms for addressing racial disparities in clinical outcomes for VA treatment for PTSD.

AUTHOR AND ARTICLE INFORMATION

U.S. Department of Veterans Affairs Northeast Program Evaluation Center, West Haven, Connecticut (Gross, Smith, Hoff, Harpaz-Rotem); Yale University School of Medicine, New Haven, Connecticut (Gross, Smith, Hoff, Harpaz-Rotem); Rocky Mountain Mental Illness Research, Education and Clinical Center for Veteran Suicide Prevention, Aurora, Colorado (Holliday); University of Colorado Anschutz Medical Campus, Aurora

(Holliday); UCF RESTORES, University of Central Florida, Orlando (Rozek). Send correspondence to Dr. Gross (georgina.gross@va.gov).

The authors report no financial relationships with commercial interests.

Received October 23, 2020; revision received March 4, 2021; accepted April 15, 2021; published online August 9, 2021.

REFERENCES

1. Fulton JJ, Calhoun PS, Wagner HR, et al: The prevalence of post-traumatic stress disorder in Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) veterans: a meta-analysis. *J Anxiety Disord* 2015; 31:98–107
2. VA/DOD Clinical Practice Guidelines for the Management of Post-traumatic Stress Disorder and Acute Stress Disorder. Washington, DC, Department of Veterans Affairs, Department of Defense, 2017. <https://www.healthquality.va.gov/guidelines/MH/ptsd/VADoDPTSDCPGFinal.pdf>
3. Yancy CW: COVID-19 and African Americans. *JAMA* 2020; 323:1891–1892
4. Carter RT, Pieterse AL: Measuring the Effects of Racism: Guidelines for the Assessment and Treatment of Race-Based Traumatic Stress Injury. New York, NY, Columbia University Press, 2020
5. Hall WJ, Chapman MV, Lee KM, et al: Implicit racial/ethnic bias among health care professionals and its influence on health care outcomes: a systematic review. *Am J Public Health* 2015; 105:e60–e76
6. Saha S, Freeman M, Toure J, et al: Racial and ethnic disparities in the VA health care system: a systematic review. *J Gen Intern Med* 2008; 23:654–671
7. McClendon J, Perkins D, Copeland LA, et al: Patterns and correlates of racial/ethnic disparities in posttraumatic stress disorder screening among recently separated veterans. *J Anxiety Disord* 2019; 68:102145
8. Dursa EK, Reinhard MJ, Barth SK, et al: Prevalence of a positive screen for PTSD among OEF/OIF and OEF/OIF-era veterans in a large population-based cohort. *J Trauma Stress* 2014; 27:542–549
9. Kaczurkin AN, Asnaani A, Hall-Clark B, et al: Ethnic and racial differences in clinically relevant symptoms in active duty military personnel with posttraumatic stress disorder. *J Anxiety Disord* 2016; 43:90–98
10. Dohrenwend BP, Turner JB, Turske NA, et al: War-related posttraumatic stress disorder in Black, Hispanic, and majority White Vietnam veterans: the roles of exposure and vulnerability. *J Trauma Stress* 2008; 21:133–141
11. Steenkamp MM, Schlenger WE, Corry N, et al: Predictors of PTSD 40 years after combat: findings from the National Vietnam Veterans Longitudinal Study. *Depress Anxiety* 2017; 34:711–722
12. Koo KH, Hebenstreit CL, Madden E, et al: PTSD detection and symptom presentation: racial/ethnic differences by gender among veterans with PTSD returning from Iraq and Afghanistan. *J Affect Disord* 2016; 189:10–16
13. Monnier J, Elhai JD, Frueh BC, et al: Replication and expansion of findings related to racial differences in veterans with combat-related PTSD. *Depress Anxiety* 2002; 16:64–70
14. Spont MR, Nelson DB, Murdoch M, et al: Are there racial/ethnic disparities in VA PTSD treatment retention? *Depress Anxiety* 2015; 32:415–425
15. Hunt MG, Rosenheck RA: Psychotherapy in mental health clinics of the Department of Veterans Affairs. *J Clin Psychol* 2011; 67:561–573
16. Spont MR, Sayer NA, Kehle-Forbes SM, et al: A prospective study of racial and ethnic variation in VA psychotherapy services for PTSD. *Psychiatr Serv* 2017; 68:231–237
17. Hebenstreit CL, Madden E, Koo KH, et al: Minimally adequate mental health care and latent classes of PTSD symptoms in female Iraq and Afghanistan veterans. *Psychiatry Res* 2015; 230:90–95

18. Spont MR, Hodges J, Murdoch M, et al: Race and ethnicity as factors in mental health service use among veterans with PTSD. *J Trauma Stress* 2009; 22:648–653
19. Lester K, Resick PA, Young-Xu Y, et al: Impact of race on early treatment termination and outcomes in posttraumatic stress disorder treatment. *J Consult Clin Psychol* 2010; 78:480–489
20. Smith NB, Tsai J, Pietrzak RH, et al: Differential predictive value of PTSD symptom clusters for mental health care among Iraq and Afghanistan veterans following PTSD diagnosis. *Psychiatry Res* 2017; 256:32–39
21. Smith NB, Cook JM, Pietrzak R, et al: Mental health treatment for older veterans newly diagnosed with PTSD: a national investigation. *Am J Geriatr Psychiatry* 2016; 24:201–212
22. Koo KH, Madden E, Maguen S: Race-ethnicity and gender differences in VA health care service utilization among US veterans of recent conflicts. *Psychiatr Serv* 2015; 66:507–513
23. Holliday RP, Holder ND, Williamson MLC, et al: Therapeutic response to cognitive processing therapy in White and Black female veterans with military sexual trauma-related PTSD. *Cogn Behav Ther* 2017; 46:432–446
24. Spont M, Nelson D, Kehle-Forbes S, et al: Racial and ethnic disparities in clinical outcomes six months after receiving a PTSD diagnosis in Veterans Health Administration. *Psychol Serv* (Epub July 13, 2020)
25. Maguen S, Madden E, Neylan TC, et al: Timing of mental health treatment and PTSD Symptom improvement among Iraq and Afghanistan veterans. *Psychiatr Serv* 2014; 65:1414–1419
26. Sripada RK, Pfeiffer PN, Rampton J, et al: Predictors of PTSD symptom change among outpatients in the US Department of Veterans Affairs health care system. *J Trauma Stress* 2017; 30:45–53
27. Sripada RK, Ready DJ, Ganoczy D, et al: When to change the treatment plan: an analysis of diminishing returns in VA patients undergoing prolonged exposure and cognitive processing therapy. *Behav Ther* 2020; 51:85–98
28. Jeffreys MD, Reinfeld C, Nair PV, et al: Evaluating treatment of posttraumatic stress disorder with cognitive processing therapy and prolonged exposure therapy in a VHA specialty clinic. *J Anxiety Disord* 2014; 28:108–114
29. Sripada RK, Blow FC, Rauch SAM, et al: Examining the nonresponse phenomenon: factors associated with treatment response in a national sample of veterans undergoing residential PTSD treatment. *J Anxiety Disord* 2019; 63:18–25
30. Cook JM, Schnurr PP, Simiola V, et al: Adoption by VA residential programs of two evidence-based psychotherapies for PTSD: effect on patient outcomes. *Psychiatr Serv* 2019; 70:553–560
31. Cook JM, O'Donnell C, Dinnen S, et al: A formative evaluation of two evidence-based psychotherapies for PTSD in VA residential treatment programs. *J Trauma Stress* 2013; 26:56–63
32. Holliday R, Smith NB, Holder N, et al: Comparing the effectiveness of VA residential PTSD treatment for veterans who do and do not report a history of MST: a national investigation. *J Psychiatry Res* 2020; 122:42–47
33. Weathers FW, Litz BT, Keane TM, et al: The PTSD Checklist for DSM-5 (PCL-5). White River Junction, VT, National Center for PTSD, 2013. <https://www.ptsd.va.gov>
34. Bovin MJ, Marx BP, Weathers FW, et al: Psychometric properties of the PTSD checklist for Diagnostic and Statistical Manual of Mental Disorders–Fifth Edition (PCL-5) in veterans. *Psychol Assess* 2016; 28:1379–1391
35. Using the PTSD Checklist for DSM-5 (PCL-5). White River Junction, VT, National Center for PTSD, 2013. www.ptsd.va.gov/professional/assessment/documents/using-PCL5.pdf
36. Kroenke K, Spitzer RL: The PHQ-9: a new depression diagnostic and severity measure. *Psychiatr Ann* 2002; 32:509–515
37. Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Rev. Washington, DC, American Psychiatric Association, 2000
38. Kroenke K, Spitzer RL, Williams JBW: The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med* 2001; 16: 606–613
39. Edwards LJ: Modern statistical techniques for the analysis of longitudinal data in biomedical research. *Pediatr Pulmonol* 2000; 30: 330–344
40. Krueger C, Tian L: A comparison of the general linear mixed model and repeated measures ANOVA using a dataset with multiple missing data points. *Biol Res Nurs* 2004; 6:151–157
41. McCoach DB: Hierarchical linear modeling; in *Quantitative Methods in the Social and Behavioral Sciences: A Guide for Researchers and Reviewers*. Edited by Hancock GR, Mueller RO. New York, Routledge, 2010
42. Singer JD, Willett JB: *Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence*. New York, Oxford University Press, 2003
43. Eliacin J, Coffing JM, Matthias MS, et al: The relationship between race, patient activation, and working alliance: implications for patient engagement in mental health care. *Adm Policy Ment Health Ment Health Serv Res* 2018; 45:186–192
44. Eliacin J, Matthias MS, Cunningham B, et al: Veterans' perceptions of racial bias in VA mental healthcare and their impacts on patient engagement and patient-provider communication. *Patient Educ Couns* 2020; 103:1798–1804
45. MacDonald S, Hausmann LRM, Sileanu FE, et al: Associations between perceived race-based discrimination and contraceptive use among women veterans in the ECUUN Study. *Med Care* 2017; 55(suppl 9 2):S43–S49
46. Castro F, AhnAllen CG, Wiltsey-Stirman S, et al: African American and European American veterans' perspectives on receiving mental health treatment. *Psychol Serv* 2015; 12:330–338
47. McGuire TG, Miranda J: New evidence regarding racial and ethnic disparities in mental health: policy implications. *Health Aff* 2008; 27:393–403
48. Holder N, Shiner B, Li Y, et al: Timing of evidence-based psychotherapy for posttraumatic stress disorder initiation among Iraq and Afghanistan war veterans in the Veterans Health Administration. *Psychol Trauma* 2020; 12:260–271
49. Jimenez DE, Bartels SJ, Cardenas V, et al: Cultural beliefs and mental health treatment preferences of ethnically diverse older adult consumers in primary care. *Am J Geriatr Psychiatry* 2012; 20:533–542
50. Fortuna LR, Alegria M, Gao S: Retention in depression treatment among ethnic and racial minority groups in the United States. *Depress Anxiety* 2010; 27:485–494
51. Sibrava NJ, Bjornsson AS, Pérez Benítez ACI, et al: Posttraumatic stress disorder in African American and Latinx adults: clinical course and the role of racial and ethnic discrimination. *Am Psychol* 2019; 74:101–116
52. Muralidharan A, Austern D, Hack S, et al: Deployment experiences, social support, and mental health: comparison of Black, White, and Hispanic US veterans deployed to Afghanistan and Iraq. *J Trauma Stress* 2016; 29:273–278
53. Bovin MJ, Black SK, Kleiman SE, et al: The impact of assessment modality and demographic characteristics on endorsement of military sexual trauma. *Womens Health Issues* 2019; 29(suppl 1):S67–S73
54. Chen R, Kessler RC, Sadikova E, et al: Racial and ethnic differences in individual-level and area-based socioeconomic status and 12-month DSM-IV mental disorders. *J Psychiatr Res* 2019; 119: 48–59
55. Seng JS, Lopez WD, Sperlich M, et al: Marginalized identities, discrimination burden, and mental health: empirical exploration of an interpersonal-level approach to modeling intersectionality. *Soc Sci Med* 2012; 75:2437–2445